In contrast to tumor gene expression, the levels of systemic CCL5, CXCL9 and CXCL10 in baseline serum samples were similar among all patients, regardless of their response to anti-HER2 antibody-based neoadjuvant treatment (Supplementary Fig. 6B). Here, CXCL9 is linked to neoplasm.